安替可胶囊联合卡培他滨和奥沙利铂治疗晚期结直肠癌的临床研究

目的探讨安替可胶囊联合卡培他滨和奥沙利铂治疗晚期结直肠癌的临床疗效。方法选取2014年2月—2015年10月在达州市中西医结合医院接受治疗的晚期结直肠癌患者84例,按照治疗方法的差别分成对照组(42例)和治疗组(42例)。对照组口服卡培他滨片,1 g/m~2,2次/d;同时静脉滴注注射用奥沙利铂,130 mg/m~2,1次/d。治疗组在对照组治疗基础上口服安替可胶囊,2粒/次,3次/d。两组患者均连续治疗9周。观察两组患者的临床疗效,同时比较治疗前后两组患者血清基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)水平,评价两组患者生存质量改善情况和不良反应发生率。结果治疗后,对照组客观缓解率(ORR)为40.48%,临床获益率(CBR)为71.43%;治疗组ORR和CBR分别为61.90%、90.48%,两组ORR、CBR比较差异具有统计学意义(P0.05)。治疗后,对照组和治疗组患者生存质量改善率分别为80.95%和95.24%,两组差异比较具有统计学意义(P0.05)。治疗后,两组患者血清MMP-2和MMP-9水平均较同组治疗前明显降低(P0.05);且治疗组上述两项指标降低的更显著(P0.05)。治疗过程中,治疗组不良反应发生率为28.57%,低于对照组的54.76%,两组不良反应发生率比较差异具有统计学意义(P0.05)。结论安替可胶囊联合卡培他滨和奥沙利铂治疗晚期结直肠癌具有很好的临床疗效,可以降低肿瘤细胞浸润和转移能力,改善患者生活质量,具有一定的临床应用推广价值。

Clinical study on Antike Capsules combined with capecitabine and oxaliplatin in treatment of advanced colorectal cancer

Objective To explore the clinical effect of Antike Capsules combined with capecitabine and oxaliplatin in treatment of advanced colorectal cancer. Methods Patients (84 cases) with advanced colorectal cancer in Dazhou Hospital of Chinese Traditional and Western Medicine from February 2014 to October 2015 were divided into control (42 cases) and treatment groups (42 cases) according to different treatment methods. The patients in the control group were po administered with Capecitabine Tablets, 1 g/m², twice daily; And they were iv administered with Oxaliplatin for injection, 130 mg/m², once daily. The patients in the treatment group were po administered with Antike Capsules on the basis of the control group, 2 grains/time, three times daily. The patients in two groups were treated for 9 weeks. After treatment, the clinical efficacies were observed, and the levels of MMP-2 and MMP-9 in two groups were compared before and after treatment, in the same time, the improvement of survival quality and incidence of adverse reactions were evaluated. Results After treatment, ORR and CBR in the control group respectively were 40.48% and 71.43%; Accordingly, they were 61.90% and 90.48% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the improvement rate of survival quality in the control and treatment groups were 80.95% and 95.24%, respectively, the difference was statistically significant in two groups (P<0.05). After treatment, the serum MMP-2 and MMP-9 levels in two groups were significantly decreased (P<0.05); The above two indexes in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). During treatment, the incidence of adverse reactions in the treatment group was 28.57%, which was lower than 54.76% in the control group, and there were differences between two groups (P<0.05). Conclusion Antike Capsules combined with capecitabine and oxaliplatin in treatment of advanced colorectal cancer have good clinical effect, can reduce the ability of tumor cell invasion and metastasis, and improve the quality of life, which has a certain clinical application value.